Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

HOUSTON, Aug. 6, 2019 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a paper entitled “Immunological Reprogramming in the CNS Tumor Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade” will be presented at the Inaugural Conference on Brain Metastases, in New York City, August 16-17, 2019.

The release as fetched from its publisher. moleculin.com ↗